Vistagen Therapeutics, Inc.

Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause

Vistagen to Participate in Upcoming Investor Conferences

Vistagen to Participate in the 46th Annual TD Cowen Healthcare Conference

Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update